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Background: The Bladder Cancer Index (BCI) is so far the only instrument applicable across all bladder cancer
patients, independent of tumor infiltration or treatment applied. We developed a Spanish version of the BCI, and
assessed its acceptability and metric properties.
Methods: For the adaptation into Spanish we used the forward and back-translation method, expert panels, and
cognitive debriefing patient interviews. For the assessment of metric properties we used data from 197 bladder cancer
patients from a multi-center prospective study. The Spanish BCI and the SF-36 Health Survey were self-administered
before and 12 months after treatment. Reliability was estimated by Cronbach’s alpha. Construct validity was
assessed through the multi-trait multi-method matrix. The magnitude of change was quantified by effect sizes to
assess responsiveness.
Results: Reliability coefficients ranged 0.75-0.97. The validity analysis confirmed moderate associations between
the BCI function and bother subscales for urinary (r = 0.61) and bowel (r = 0.53) domains; conceptual independence
among all BCI domains (r ≤ 0.3); and low correlation coefficients with the SF-36 scores, ranging 0.14-0.48. Among
patients reporting global improvement at follow-up, pre-post treatment changes were statistically significant for
the urinary domain and urinary bother subscale, with effect sizes of 0.38 and 0.53.
Conclusions: The Spanish BCI is well accepted, reliable, valid, responsive, and similar in performance compared to
the original instrument. These findings support its use, both in Spanish and international studies, as a valuable and
comprehensive tool for assessing quality of life across a wide range of bladder cancer patients.
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Bladder cancer is one of the most complex neoplasms in
urologic oncology. In men it is the fourth leading cancer
location in the European Union and the United States
[1,2]. Estimated incidence rates for men are lower in
Europe than in the United States (29.1 vs 37.6 per
100,000); however, the rate for Spanish males is among
the highest in the European Union (39.0 per 100,000).* Correspondence: mferrer@imim.es
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stated.Spanish men present about eight times higher incidence
rates than Spanish women [1].
Health-related quality of life (HRQL) is an important
outcome for evaluating the impact of disease and for
monitoring treatment benefits and side effects. Since
bladder cancer survivors have usually undergone several
treatments, measuring HRQL with valid instruments is of
value for clinicians and patients when making informed
decisions based on patients’ experiences [3]. Although
HRQL assessment is an essential endpoint in clinical trials
[4] and comparative effectiveness research [5], it is still in-
frequently used in bladder cancer studies [6].
Almost all of the specific HRQL questionnaires avail-
able for bladder cancer were either developed by thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Cancer (EORTC) or the American organization for Func-
tional Assessment of Cancer Therapy (FACT). Both rec-
ommend measuring HRQL with their general wellbeing
core questionnaire for oncologic patients plus a specific
module. The EORTC-QLQ-BLS24 and the FACT-Bladder
modules are applicable for patients with superficial blad-
der cancer; while the EORTC-QLQ-BLM30 and the FACT
Vanderbilt Cystectomy Index are for patients at muscle
invasive stage [7-9]. These modules were designed for
specific grades of tumor infiltration and types of treat-
ment (mainly transurethral resection or cystectomy),
which leads to certain difficulties when dealing with
mixed patient characteristics in clinical practice or with
comparative research on effectiveness.
The Bladder Cancer Index (BCI) [10,11] was developed
in the United States (2007) to overcome this limitation,
as it contains neutral questions regarding native or neo-
bladder, urinary diversion method, and gender. It is there-
fore comprehensive across a wide range of bladder cancer
patients, independent of tumor infiltration and treatment
applied. It has shown to be a robust multidimensional
HRQL measure. The BCI development process included
a literature review, an expert panel study, and input
from bladder cancer survivors who reviewed the con-
tent before pilot testing. The BCI demonstrated high
internal consistency and test-retest reliability, interscale
independence among domains [11] and different HRQL
profiles among treatments [10].
HRQL is a standard outcome in clinical trials [4], with in-
creasing need for available measures in different languages
to perform international multi-center studies. Therefore,
the aim was to linguistically and culturally adapt the BCI
for its use in Spain, and to test the acceptability, reliability,
validity, and responsiveness of this adapted version.
Methods
The Bladder Cancer Index (BCI)
The BCI consists of 36 items, with 4- or 5-point Likert
response scales, covering 3 primary domains: urinary
(14 items), bowel (10 items), and sexual (12 items). For
each domain a summary score and two subscale scores
(function and bother) are constructed. The function
items focus on the frequency of the disease symptoms,
with answer scales such as: “Never, rarely, about half the
time, usually, or always”. The items of bother reflect the
individual perception of these symptoms, usually catego-
rized as: “No problem, very small, small, moderate, or big
problem”. Following the algorithm developed by the au-
thors of the original instrument [11], scores are calculated
by transforming item responses into a 0 to 100 scale and
calculating the mean of the standardized items. Higher
scores indicate better health status. To calculate a score, a
minimum of 80% completed items is required.Linguistic and cultural adaptation
Standard methods were used to translate and culturally
adapt the instrument [12]. The Spanish translation of
the BCI was carried out independently by two profes-
sional linguists, both native Spanish speakers, with a
high level of fluency in English. The focus of these for-
ward translations was achieving a conceptual, rather
than literal, equivalence. Afterwards, an interdisciplinary
group of researchers (two experts in quality of life assess-
ment, an urologist, and an oncologic nurse) reviewed the
two BCI translations and reached a consensus version.
Cognitive debriefing interviews were held to explore
the understandability of this preliminary version, and to
identify discrepancies with the original BCI. Individual-
ized interviews were carried out with 11 patients (9 of
which had non-muscle invasive bladder cancer and 2
had muscle-invasive disease) who were aged 54-82 years
old. This technique allowed assessing what the patient
understood in the adapted version. Only minor changes
were included as a result of patients’ feedback because
they found the Spanish BCI version to be understand-
able and adequate. The resulting modification was the
omission of brand names, as most Spanish patients are
not aware of the name of their specific urinary diversion.
As a last step, this pre-final version was translated
back into English by a native American-English speaker.
The original and back-translated versions were compared
and sent to the author of the original BCI for evaluation.
Since no major discrepancies were found, no changes were
introduced in the final Spanish version.
Study of metric properties
The psychometric properties of the questionnaire were
tested in a subsample of bladder cancer patients from
a multi-center prospective study. This study was con-
ducted from October 2010 to September 2011 and fo-
cused on the clinical care process and health outcomes
of patients with urologic tumors. Briefly, patients were
consecutively enrolled from the urologic departments of
7 hospitals in 5 Spanish autonomous regions. The inclu-
sion criteria were 1) having an anatomopathological con-
firmation of bladder cancer during the study period, 2)
being diagnosed and treated in one of the study hospi-
tals, and 3) agreeing to participate in the study and to
sign an informed consent form. The study was approved
by the corresponding ethic committees.
Clinical data were retrieved from medical records, and
HRQL data were collected before and 12 months after
treatment. Patients self-completed the SF-36 and the
BCI during their outpatient visits. The short-form health
questionnaire SF-36 (version 2) [13] is a 36-item generic
HRQL questionnaire covering eight dimensions, which
can be summarized into a physical and a mental com-
ponent summary score (PCS and MCS, respectively).
Table 1 Demographic and clinical characteristics of
bladder cancer patients
N (%)
Total patients 197
Age
Mean (standard deviation) 69.3 (11)
Sex
Male 171 (86.8)
Female 26 (13.2)
Tumor histology
Adenocarcinoma 17 (10.2)
Transitional cell carcinoma 116 (69.9)
Squamous-cell carcinoma 3 (1.8)
Others 30 (18.1)
Missing 31 (15.7)
Disease stage
Tx 5 (2.5)
Ta 58 (29.4)
Tis 5 (2.5)
T1 102 (51.8)
T2a 16 (8.1)
T2b 6 (3.0)
T3 3 (1.5)
T4 2 (1.0)
Missing 11 (5.6)
Medical treatment
Transurethral resection 183 (96.3)
Radical cystectomy 6 (3.2)
Bacillus Calmette–Guérin 33 (17.4)
Chemotherapy 24 (12.6)
Radiotherapy 3 (1.6)
Missing 7 (3.6)
Education
Incomplete studies 62 (31.5)
Primary or secondary studies 103 (52.6)
Superior studies 31 (15.9)
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and a standard deviation of 10 in the U.S. general popu-
lation [13]. Scores above or below 50 indicate better or
worse health status compared to the general population.
The post-treatment interview additionally included a
question on global health change: “How would you rate
your current bothers related with your bladder tumor
compared to those before treatment (1 year ago)? You
feel better; You feel the same; You feel worse”. Those
patients who reported complete HRQL data at baseline
and 12 months after treatment, as well as the question
on global change, were selected to compose the BCI val-
idation subsample. Its sample size (n = 197) gave a statis-
tical power of 0.8 to detect small differences of five
points on the urinary summary score between pre- and
post-treatment, using a two-sided paired t-test with a
type I error of 5%.
Statistical analysis
Mean, standard deviations, score range, and percentage
of patients with the worst possible (floor effect) and best
possible theoretical scores (ceiling effect) were calculated
in order to examine the score distribution. Cronbach’s
alpha coefficient was calculated to assess reliability based
on internal consistency [14]. To provide the most similar
comparison possible with the original BCI study, all
the analyses were conducted with the 12 month post-
treatment data, except for the responsiveness evalu-
ation, where pre- and post-treatment data were used.
To assess construct validity, interscale correlations
(Pearson coefficients) between the BCI domains and
subscales and with the SF-36 scores (multi-trait multi
method matrix) were calculated. Pre-specified hypothesis
were that: a) Function and bother subscales within each
individual BCI domain present moderate correlation, as
bother subscales quantify the symptoms’ impact, mea-
sured by the function subscales; b) In contrast, corre-
lations among different BCI domains are low since
urinary, sexual, and bowel domains measure different
HRQL components; and c) Correlations between BCI
and SF-36 scores are moderate to low, due to differences
between generic and disease-specific instruments. Corre-
lations of <0.45, 0.45-0.70, and >0.70 were considered as
low, moderate, and high, respectively [15].
To evaluate responsiveness, pre- and post-treatment
mean scores were compared using a paired t-test among
patients reporting improvement in the global health
change question. To quantify the magnitude of change,
effect sizes were calculated as the mean score differences
divided by the standard deviation of pre-treatment
scores. Effect sizes of 0.2, 0.5 and 0.8 were defined as
small, moderate and large, respectively [16]. Analyses
were carried out with SPSS statistics software, version 12
(SPSS, Chicago, IL, USA).Results
Table 1 shows the clinical and demographic characteristics
of the 197 patients with bladder cancer who composed
the BCI validation subsample. Patients were mainly men
(86.8%) with a mean age of 69 years. Transitional cell
carcinoma was the most prevalent (70%) and 84% of pa-
tients were diagnosed at non-muscle invasive stages
(Ta, Tis, or T1). Transurethral resection (TUR) was the
primary treatment applied (96.3%), in some cases com-
bined with either Bacillus Calmette–Guérin (17.4%) or
Table 2 BCI scores distribution and internal consistency
BCI domains N° items Mean (SD) Missing items Missing score Observed range Floor effect Ceiling effect Cronbach’s alpha
Urinary 14 88.8 (19.3) 15.7 8.6 0 – 100 0.6 50.0 0.92
Function 6 88.2 (24.4) 7.6 7.6 0 – 100 2.7 71.4 0.91
Bother 8 89.2 (20.0) 13.7 10.2 0 – 100 0.6 58.2 0.90
Bowel 10 90.1 (14.7) 7.6 2.5 13.9 – 100 0 34.4 0.84
Function 4 92.4 (15.1) 4.1 4.1 6.3 – 100 0 57.7 0.75
Bother 6 89.0 (17.2) 6.1 3.0 20.0 – 100 0 51.3 0.78
Sexual 12 51.5 (24.0) 17.8 12.7 6.8 – 100 0 2.9 0.88
Function 7 31.2 (32.1) 15.2 10.7 0 – 100 33.0 4.0 0.97
Bother 5 79.3 (29.8) 15.2 12.7 0 – 100 0.6 58.1 0.86
Missing items: percentage of patients with any missing items; Missing score: percentage of patients with any missing score; Floor effect: percentage of patients
with worst possible score (0); Ceiling effect: percentage of patients with best possible score (100).
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up, three patients developed metastasis (two to the lung
and one lymphatic) and 36 patients presented cancer re-
currence or progression (18.3%). At the end of the
study, 23 of these patients were in complete remission.
The percentage of patients with any missing item in
urinary, bowel or sexual domains was 15.7%, 7.6% and
17.8%, respectively (Table 2). The proportion of insufficient
information to calculate the score (missing items > 20%)
was the highest for the sexual (10.7-12.7%) and the lowest
for the bowel domain (2.5-4.1%). No floor effect was found
except for the sexual function domain (33%). Ceiling
effects were observed in all domains, being the highest in
the urinary function subscale (71.4%), and the lowest for
the sexual summary (2.9%). All Cronbach’s alpha values
were high, ranging 0.75-0.97.
Table 3 shows the multi-trait multi-method matrix of
correlations with the BCI and with the SF-36 scores. As
previously hypothesized, the strength of the associationTable 3 Correlations among BCI subscales and SF-36 summar
Urinary
B C I
Function Bother
Urinary
Function 1
Bother 0.61 1
Bowel
Function 0.09 0.26
Bother 0.11 0.32
Sexual
Function 0.27 0.28
Bother 0.05 0.12
S F – 3 6
SF-36
PSC 0.28 0.44
MSC 0.24 0.48
Correlations (Pearson coefficients) previously hypothesized as moderate are markedbetween symptom severity (function subscale) and its
impact (bother subscale) was moderate for each specific
BCI domain, with Pearson coefficients of 0.61 and 0.53
marked in bold. Only for the sexual domain we observed a
low correlation (r = 0.15). BCI domain subscales presented
low correlations (<0.30) with the other BCI domains.
Finally, most of the correlation coefficients between BCI
and SF-36 scores were lower than 0.40.
Responsiveness was evaluated in the group of 110 pa-
tients who reported improvement 12 months after treat-
ment (Figure 1). The median follow-up time between
pre and post-treatment evaluation was 424 days. Change
between pre- and post-treatment indicated a statistically
significant improvement in the BCI urinary summary
(effect size =0.38, p =0.003) and urinary bother subscale
(effect size =0.53, p <0.001). No statistically significant
changes were observed on bowel scores. Sexual function
showed statistically significant worsening of small mag-
nitude (effect size =0.29, p =0.009).y component scores
Bladder Cancer Index (BCI)
Bowel Sexual
Function Bother Function Bother
1
0.53 1
0.14 0.26 1
0.10 0.11 0.15 1
0.23 0.34 0.28 0.14
0.27 0.36 0.19 0.16
in bold.
    BCI Urinary Domain
     BCI Sexual Domain     SF-36 Component Summaries
0
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Sexual    S-Function *    S-Bother
ES= 0.18 ES= 0.29 ES= -0.06 
0
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ES= -0.53 ES= 0.00 ES= -0.38 
0
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100
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BCI Bowel Domain
Figure 1 Responsiveness to health change in patients who reported improvement 12 months after treatment (n = 110). Footnote: Bars
with points reflect the pre-treatment scores; bars with stripes the post-treatment scores. Confidence interval 95%. *indicate statistical significance
between pre- and post-treatment scores with p < 0.05. ES: effect size.
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We used a standard cross-cultural adaptation process to
develop the Spanish BCI version, which demonstrated a
good patient acceptability, high reliability, good con-
struct validity, and sensitivity to change over time. The
results are consistent with those obtained for the ori-
ginal BCI and suggest that the Spanish version is con-
ceptually and metrically equivalent.
Regarding acceptability, the relatively high percentage of
patients with any missing items (27%) may indicate some
problems. However, the number of missing items per pa-
tient was low, with a mean of 2.2 (standard deviation = 5),
and the percentage of missing per item ranges from 0.5% to
14% of patients. The fact that missing values were not con-
centrated in specific items or domains supports the idea
that the BCI did not include any unsuitable or irrelevant
item, and that it was well accepted by Spanish patients. In
terms of reliability, as Cronbach’s alpha coefficients were
above the standard of 0.7 [14], all summary and subscalescores can be used for comparing groups of patients. Urin-
ary scores achieved the more demanding standard of 0.9
for individual comparisons (individual change over time, or
differences among individuals). These results are very simi-
lar to the reliability coefficients reported for the original
version (Cronbach’s alpha 0.77-0.94).
The high ceiling effect observed on urinary and bowel
domains, especially for the function subscale, is congru-
ent with the clinical characteristics of our patient sam-
ple. The maximum score means good function and no
bother, which is the case when dealing with patients di-
agnosed at a superficial disease stage, as in more than
80% of our sample. The ceiling effect for the sexual do-
main was specially marked on the bother subscale,
where almost 60% of patients reported no sexual bother.
Ceiling effects reported by the study of the original
instrument were also mainly on the function subscale
for urinary domain and on bother subscale for sexual
domain.
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subscales deserves a comment because it was unexpect-
edly low compared with the original study. A previous
study assessing country differences in localized prostate
cancer [17] showed that a higher percentage of patients
in Spain tend to report low sexual functioning than in
the USA. Our patients also presented low sexual func-
tioning and did not perceive this dysfunction as a
bother. Although cross-cultural differences should not
be discarded, it may be due to the fact that sexual prob-
lems could have appeared some time ago and become
accepted as a “normal” consequence of ageing, not relat-
ing them to bladder cancer or its treatment.
Unlike prior FACT Bladder or FACT Vanderbilt Cyst-
ectomy Index specific modules, which only provide an
overall score [8], BCI allows separate scores for the three
distinct domains facilitating a more detailed HRQL pro-
file of bladder cancer disease impact. The conceptual
independence among urinary, bowel, and sexual do-
mains was supported by the low interscale correlations
(ranging from 0.05 to 0.32), which were very similar to
those reported by the original version (range 0.17-0.39).
The low correlations obtained with the SF-36 suggest
that BCI captures additional information which is not
covered by generic instruments.
The moderate urinary changes observed between pre-
and post-treatment evaluations of patients perceiving im-
provement after treatment demonstrate the BCI’s respon-
siveness over time. Furthermore, the high percentage of
patients diagnosed at initial stages and treated with min-
imal invasive techniques (i.e. endoscopic removal of can-
cerous tissue) explains the small sexual worsening and the
bowel stability observed. These results are consistent with
the original BCI cross-sectional study comparing groups
with different surgical approaches [11].
Some study limitations deserve further comment. First,
our study design differed substantially from the design
of the original BCI study. Gilbert et al [9,10] obtained
the HRQL assessment of patients at 1 to10 years after
diagnosis, while our HRQL evaluation was performed
1 year after. Second, cancer stage homogeneity of our
sample (84% with non-muscle invasive disease) limits
the generalizability of results to patients with advanced
disease, and did not allow a comparison among different
therapeutic groups. However, results from the original
USA study, with a sample composed by 40% of patients
at muscle-invasive disease stages and 70% with high
grade tumors, support the suitability of BCI across the
wide spectrum of this disease. Third, because our study
mainly included men, generalizing our results to women
with bladder cancer is uncertain. Finally, our study
design did not allow test-retest analysis to assess the
questionnaire’s repeatability, but the BCI’s high internal
consistency supports adequate reliability.Conclusions
Researchers and clinicians now have at their disposal
a bladder cancer-specific HRQL instrument for use
in Spanish patients that is applicable across the wide
spectrum of this disease. Our results suggest the multi-
dimensionality of the Spanish BCI version, and provide
considerable evidence about its appropriate metric
properties, including responsiveness to health changes
over time even in patients treated with non-invasive
techniques. Comparison with the original U.S. version
shows that it is similar in reliability and validity,
suggesting that the cross-cultural adaptation method
followed has yielded an equivalent Spanish version.
Moreover, proofs supporting the BCI as a valuable tool
for assessing HRQL in patients within the whole blad-
der cancer spectrum are strengthened by the demon-
stration of its appropriateness in a different language
and culture [18] and reinforces its usefulness for inter-
national studies.
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